Glossary

ORBIT Bleeding Risk Score

The ORBIT score estimates a person's risk of major bleeding when they take an anticoagulant for Atrial Fibrillation. NICE recommends it over other bleeding risk tools, such as HAS-BLED, when starting or reviewing anticoagulation.

Clinically reviewed by Aisha Malik, Clinical Director (GPhC 2205843), on .

What it means in practice

NICE's Atrial Fibrillation guideline (NG196, 2021) recommends the CHA2DS2-VASc score to assess stroke risk and the ORBIT score to assess bleeding risk. The committee chose ORBIT because it was better calibrated at all levels of bleeding risk and better at predicting the absolute risk of intracranial haemorrhage. ORBIT scores five factors: older age (75 or over), reduced haemoglobin, haematocrit or a history of anaemia, a history of bleeding, reduced kidney function, and treatment with an antiplatelet. The score informs a conversation about risk; it isn't a reason on its own to withhold anticoagulation. NICE also recommends addressing modifiable bleeding risk factors, including reversible causes of anaemia. Some systems still calculate HAS-BLED, which can be used until ORBIT is embedded in local pathways.

Good practice

  • Record CHA2DS2-VASc and ORBIT scores at each anticoagulation review
  • Look for modifiable risk factors, such as anaemia, uncontrolled blood pressure or an antiplatelet that may no longer be needed
  • Use the score to support a shared decision, not to stop anticoagulation by itself
  • Repeat the assessment when the person's circumstances change

Questions

Why does NICE prefer ORBIT to HAS-BLED?

NICE's committee found ORBIT was better calibrated at all levels of major bleeding risk and better at predicting the absolute risk of intracranial haemorrhage.

Does a high ORBIT score mean anticoagulation should stop?

No. The score informs a discussion of benefits and risks and prompts action on modifiable risk factors. The decision is made with the person, alongside their stroke risk.

Sources

Checked against these sources on 19 November 2026.

  1. Atrial fibrillation: diagnosis and management, NG196 (NICE)
  2. NG196 rationale and impact: bleeding risk (NICE)
  3. Anticoagulation part 1: non-valvular atrial fibrillation briefing (PrescQIPP)

Remote clinical pharmacists, funded through ARRS.

Book a 30-minute call